Protein nmb0928 and use thereof in pharmaceutical formulations

Details Protein nmb0928 and use thereof in pharmaceutical formulations Protein nmb0928 and use thereof in pharmaceutical formulations

C - Chemistry, Metallurgy

07

K

C07K 14/22 (2006.01) A61K 39/095 (2006.01) A61K 39/39 (2006.01) A61K 48/00 (2006.01) C12N 15/31 (2006.01) G01N 33/569 (2006.01)

Patent

CA 2547537

The invention relates to the use of a novel vaccine antigen which is used preventively or therapeutically against diseases of bacterial, viral, cancerous or other origin. The technical aim of the invention is to develop formulations that can increase the protective spectrum of existing vaccines and extend same against different pathogens. For said purpose, protein NMB0928 was isolated and identified as a component of Neisseria meningitidis outer membrane preparations, which can induce bactericide activity. In addition, the gene coding for protein NMB0928 was cloned and expressed, said protein being purified, and the immunogenicity thereof in animal biomodels was subsequently evaluated. The high conservation level of the sequencing of homologous genes demonstrated the high value thereof as an antigen that induces a cross immune response when presented in different ways. The resulting formulations are suitable for use in the pharmaceutical industry as vaccine formulations for human use.

L'invention concerne l'utilisation préventive ou thérapeutique d'un nouvel antigène vaccinal contre des maladies bactériennes, virales, cancéreuses, ou d'origine autre. L'objectif technique de l'invention est la mise au point de formulations permettant d'augmenter le degré de protection des vaccins existants et d'étendre celui-ci à différents agents pathogènes. Cet objectif est atteint grâce à l'isolement et à l'identification de la protéine NMB0928 comme composant des préparations de membrane externe Neisseria meningitidis, pouvant induire une activité bactéricide. Le gène codant pour la protéine NMB0928 est, de plus, cloné et exprimé, et ladite protéine purifiée, son antigénicité étant ensuite évaluée dans des biomodèles animaux. Le séquençage de gènes homologues a mis en évidence, par son degré élevé de conservation, sa valeur élevée comme antigène induisant une réponse immune croisée lorsqu'il est présenté par différentes voies. Les formulations obtenues peuvent être utilisées dans l'industrie pharmaceutique comme formulations vaccinales utilisées chez les humains.

Affiliated with

Also associated with

Rating

Protein nmb0928 and use thereof in pharmaceutical formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein nmb0928 and use thereof in pharmaceutical formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein nmb0928 and use thereof in pharmaceutical formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2012434